| Outcome Measures: |
Primary: Changes in Glycosylated Hemoglobin A1c (HbA1c), Changes in Glycosylated Hemoglobin A1c relative to baseline at 16 weeks compared to placebo., 16 weeks | Secondary: the proportion of subjects whose Glycosylated Hemoglobin A1c (HbA1c) was less than 7%., At the end of 16 weeks, the proportion of subjects whose Glycosylated Hemoglobin A1c was less than 7% ., 16 weeks|The proportion of subjects with Glycosylated Hemoglobin A1c (HbA1c) < 6.5%, The proportion of subjects with Glycosylated Hemoglobin A1c \< 6.5% at 16 weeks after administration of SY-004., 16 weeks|Changes in Glycosylated Hemoglobin A1c (HbA1c), The change of Glycosylated Hemoglobin A1c relative to the baseline after 8 weeks of treatment with SY-004., 8 weeks|the proportion of subjects whose Glycosylated Hemoglobin A1c (HbA1c) was less than 7%, At the end of 8 weeks, the proportion of subjects whose Glycosylated Hemoglobin A1c was less than 7% ., 8 weeks|The proportion of subjects with Glycosylated Hemoglobin A1c (HbA1c) < 6.5%, The proportion of subjects with Glycosylated Hemoglobin A1c \< 6.5% at the end of 8 weeks., 8 weeks|Changes in fasting blood glucose (FPG) relative to the baseline, Changes in fasting blood glucose (FPG) relative to the baseline at 1, 2, 4, 8, 12 and 16 weeks after administration of SY-004., 1、2、4、8、12、16weeks|Changes in postprandial blood glucose auc0-2h, Changes in postprandial blood glucose auc0-2h ( 0-2h blood glucose AUC of Mixed-Meal-Tolerance-Test ) relative to baseline at 16 weeks after administration of SY-004., 16 weeks|Changes in abdominal weight relative to baseline at 8 and 16 weeks., Changes in abdominal weight relative to baseline at 8 and 16 weeks after administration of SY-004., 8、16weeks
|
